European Companies Search Engine
UK funding (£10M): Building a UK IntraCellular Drug Delivery Centre (ICDDC) Ukri1 Jan 2023 UK Research and Innovation, United Kingdom
Overview
Text
Building a UK IntraCellular Drug Delivery Centre (ICDDC)
| Abstract | Ribonucleic acid (or RNA) based therapy is the treatment or prevention of diseases using RNA-based molecules. The recent sucess of messenger RNA vaccines in response to the COVID-19 pandemic has highlighted the potential of this technology and greatly increased research and industrial interest. RNA offers the potential to produce almost any functional protein or peptide in the human body by introducing mRNA as a vaccine or therapeutic agent. RNA therapeutics and vaccines often require specific, targeted delivery to be effective medicines, and a leading technology platform is Lipid Nanoparticles, along with alternative Nano Delivery Systems. This applies to a range of RNA based therapies such as mRNA/self-amplifying RNA, siRNA, antisense oligos, as well as cutting-edge and potentially curative therapeutic approaches such as gene editing technology, via CRISPR/Cas9, base or prime editing. There is an opportunity to "anchor" commercial scale design and manufacturing of these new classes of therapies in the UK and act as a global hub for research, development activities and trials -- but given the early stage of this technology it requires investment in early to mid-stage R&D to solve scientific, manufacturing, clinical and commercial challenges. Challenges to address include: creating more thermostable medicines; understanding and controlling immunogenicity and adverse reactions, developing better characterisation methods; more efficient and high productivity process development and manufacturing; and targeting a range of different organs and cell types to enable the treatment of a wider range of diseases. We are proposing to upgrade existing facilities to create state of the art capability, along with an ambitious, large scale research programme focused on building the knowhow to create disruptive innovation in the field of product design, formulation, manufacture and characterisation. This includes the ability to rationally design next generation LNPs, create a step change in the area of in vitro methods to predict drug/ vaccine human clinical response, and finally develop a digitally enabled LNP manufacturing process that will act as a lighthouse project for advanced manufacture in Pharma. With public investment we will create the knowhow and capability to catalyse an explosion of R&D investment in the UK - increasing the translation of our high quality academic base, boosting industrial R&D, clinical trials and ultimately creating a new ecosystem via company growth, enhanced productivity, onshoring and supply chain development. |
| Category | Centres |
| Reference | 10058505 |
| Status | Active |
| Funded period start | 01/01/2023 |
| Funded period end | 31/03/2026 |
| Funded value | £10,000,000.00 |
| Source | https://gtr.ukri.org/projects?ref=10058505 |
Participating Organisations
| CENTRE FOR PROCESS INNOVATION LIMITED |
£4,873,312.00 |
| MEDICINES DISCOVERY CATAPULT LIMITED |
£1,172,650.00 |
| UNIVERSITY OF LIVERPOOL |
£1,348,778.00 |
| UNIVERSITY OF STRATHCLYDE |
£1,293,450.00 |
| IMPERIAL COLLEGE LONDON |
£1,311,810.00 |
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Centre for Process Innovation Ltd., Redcar.
The visualizations for "Centre for Process Innovation Ltd. - UK funding (£10M): Building a UK IntraCellular Drug Delivery Centre (ICDDC)"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
